Evidence map›Paper›PMID 28027003›Full record

ArticleCell cycle (Georgetown, Tex.)2017

LZAP is a novel Wip1 binding partner and positive regulator of its phosphatase activity in vitro.

J Jacob Wamsley, Natalia Issaeva, Hanbing An, Xinyuan Lu, Lawrence A Donehower, Wendell G Yarbrough

Open access · bronzeAbstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
0.9field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 16 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. LZAP: A break on phosphorylation.Cell cycle (Georgetown, Tex.) · 2017
    Article
  9. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

6 authors at 5 institutions in 1 country.

J Jacob Wamsleya Department of Surgery, Division of Otolaryngology , Yale University , New Haven , CT , USA.
Natalia Issaevaa Department of Surgery, Division of Otolaryngology , Yale University , New Haven , CT , USA.
Hanbing Anc Department of Surgery , Vanderbilt University , Nashville , TN , USA.
Xinyuan Lud Department of Medicine , University of California San Francisco , San Francisco , CA , USA.
Lawrence A Donehowere Department of Molecular Virology and Microbiology , Baylor College of Medicine , Houston , TX , USA.
Wendell G Yarbrougha Department of Surgery, Division of Otolaryngology , Yale University , New Haven , CT , USA.
Yale Cancer Center · USBaylor College of Medicine · USUniversity of California, San Francisco · USVanderbilt University · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
NCATS NIH HHS UL1 TR001863
6 · The paper itself

Abstract

The phosphatase Wip1 attenuates the DNA damage response (DDR) by removing phosphorylation marks from a number of DDR proteins (p53, MDM2, Chk1/2, p38). Wip1 also dephosphorylates and inactivates RelA. Notably, LZAP, a putative tumor suppressor, has been linked to dephosphorylation of several of these substrates, including RelA, p38, Chk1, and Chk2. LZAP has no known catalytic activity or functional motifs, suggesting that it exerts its effects through interaction with other proteins. Here we show that LZAP binds Wip1 and stimulates its phosphatase activity. LZAP had been previously shown to bind many Wip1 substrates (RelA, p38, Chk1/2), and our results show that LZAP also binds the previously identified Wip1 substrate, MDM2. This work identifies 2 novel Wip1 substrates, ERK1 and HuR, and demonstrates that HuR is a binding partner of LZAP. Pleasingly, LZAP potentiated Wip1 catalytic activity toward each substrate tested, regardless of whether full-length substrates or phosphopeptides were utilized. Since this effect was observed on ERK1, which does not bind LZAP, as well as for each of 7 peptides tested, we hypothesize that LZAP binding to the substrate is not required for this effect and that LZAP directly binds Wip1 to augment its phosphatase activity.

Indexed as

BiocatalysisCell Line, TumorHEK293 CellsHumansNerve Tissue ProteinsPhosphopeptidesPhosphoprotein PhosphatasesPhosphorylationProtein BindingSubstrate SpecificityNerve Tissue ProteinsPhosphopeptidesPhosphoprotein PhosphatasesC53CDK5RAP3LZAPphosphatase regulatorPP25; Wip1PPM1D

Identifiers

PMID28027003
PMCPMC5283812
OpenAlexW2565622693

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.